Cailin Conner

DocwireNews

In pediatric patients with sick cell disease (SCD), red blood cell (RBC)&nbsp;transfusion during proinflammatory events was found to increase alloimmunization, which was not mitigated by hydroxyurea (HU), according to a recent study published in <a href="https://ashpublications.org/bloodadvances/article/7/17/4799/495234/Proinflammatory-state-promotes-red-blood-cell?searchresult=1">Blood</a>.RBC alloimmunization increases the risk of hemolytic transfusion reactions in patients with SCD and makes it difficult to find compatible blood for future transfusions. HU, a progressively utilized therapy for SCD prevention, triggers myelosuppression and diminishes inflammation. Researchers in the departments of hematology and pathology at St. Jude Children&rsquo;s Research Hospital conducted a retrospective cohort study in pediatric patients with SCD &ldquo;to explore the risk factors for alloimmunization, focusing on the roles of the recipients&rsquo; proinflammatory state, HU therapy, and Rh variants in alloimmunization.&rdquo;Of the 471 patients included in the study, the average age was 12.9 years and 99.2% of patients self-identified as Black. The most commonly observed hemoglobin (Hb) genotypes were Hb S (HbSS) and HbS&beta;0-thalassemia (81.5%). The overall alloimmunization rate was 11.7%. These patients formed 59 alloantibodies and 17 autoantibodies, with an alloimmunization rate of 0.36 alloantibodies per 100 units.The investigators noted that alloimmunization of patients who received episodic transfusion was not reduced by HU therapy (P=.071), HU therapy duration (P=.056), or HU dose (P=.242). &ldquo;The risk of alloimmunization was also higher for patients with HbSS and HbS&beta;0-thalassemia genotypes and those with a high transfusion burden,&rdquo; they wrote.A further analysis of 27 patients whose alloantibodies were formed with specificities showed 23.8% of units transfused during a proinflammatory event resulting in alloantibody formation compared with 2.8% of units transfused at a steady state, suggesting transfusion during proinflammatory events increased the risk for alloimmunization (P=.003).&ldquo;Judicious use of transfusion during proinflammatory events is critical for preventing alloimmunization,&rdquo; the investigators concluded.In pediatric patients with sick cell disease (SCD), red blood cell (RBC)&nbsp;transfusion during proinflammatory events was found to increase alloimmunization, which was not mitigated by hydroxyurea (HU), according to a recent study published in <a href="https://ashpublications.org/bloodadvances/article/7/17/4799/495234/Proinflammatory-state-promotes-red-blood-cell?searchresult=1">Blood</a>.RBC alloimmunization increases the risk of hemolytic transfusion reactions in patients with SCD and makes it difficult to find compatible blood for future transfusions. HU, a progressively utilized therapy for SCD prevention, triggers myelosuppression and diminishes inflammation. Researchers in the departments of hematology and pathology at St. Jude Children&rsquo;s Research Hospital conducted a retrospective cohort study in pediatric patients with SCD &ldquo;to explore the risk factors for alloimmunization, focusing on the roles of the recipients&rsquo; proinflammatory state, HU therapy, and Rh variants in alloimmunization.&rdquo;Of the 471 patients included in the study, the average age was 12.9 years and 99.2% of patients self-identified as Black. The most commonly observed hemoglobin (Hb) genotypes were Hb S (HbSS) and HbS&beta;0-thalassemia (81.5%). The overall alloimmunization rate was 11.7%. These patients formed 59 alloantibodies and 17 autoantibodies, with an alloimmunization rate of 0.36 alloantibodies per 100 units.The investigators noted that alloimmunization of patients who received episodic transfusion was not reduced by HU therapy (P=.071), HU therapy duration (P=.056), or HU dose (P=.242). &ldquo;The risk of alloimmunization was also higher for patients with HbSS and HbS&beta;0-thalassemia genotypes and those with a high transfusion burden,&rdquo; they wrote.A further analysis of 27 patients whose alloantibodies were formed with specificities showed 23.8% of units transfused during a proinflammatory event resulting in alloantibody formation compared with 2.8% of units transfused at a steady state, suggesting transfusion during proinflammatory events increased the risk for alloimmunization (P=.003).&ldquo;Judicious use of transfusion during proinflammatory events is critical for preventing alloimmunization,&rdquo; the investigators concluded.

Eric Bergson, MD

Rob Dillard

The Role of Multidisciplinary Care in Head and Neck Cancer

Head and Neck Cancer

Sara Nunnery, MD, MSCI

Trastuzumab Deruxtecan in HER2-Low Breast Cancer: Who’s the Right Patient?

HER2 Breast Cancer

Meghan Sise, MD

Joel M. Topf, MD, FACP

Redefining Carboplatin Dosing

NKF Spring Clinical Meetings 2025

Latest News

RBC Transfusion Linked to Higher Risk of Alloimmunization in Pediatric Patients With Sickle Cell Disease

Sickle Cell Disease

In pediatric patients with sick cell disease, red blood cell transfusion increases alloimmunization.

RBC Transfusion Linked to Higher Risk of Alloimmunization in Pediatric Patients With Sickle Cell Dis

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe